Livisto Boflox Flavor (Bofloks) flavored tablets 20 mg for dogs.
Indications for selected target species: Treatment of infections caused by marbrofloxacin-susceptible strains of microorganisms.
• infections of the skin and soft tissues (dysfunction of skin folds, impetigo, folliculitis, furunculosis, cellulitis)
• urinary tract infections associated or not associated with prostatitis or epididymitis
• respiratory tract infections.
Boflox 20 mg flavored tablets for dogs
QUALITATIVE AND QUANTITATIVE COMPOSITION:
Each tablet contains:
Active ingredient:
Marbofloxacin 20 mg
PHARMACEUTICAL FORM:
Tablet. Longitudinal beige tablets with brown spots with a dividing line on both sides. The tablets can be divided in half.
DETAILED CLINICAL DATA
Target species of animals:
dogs
Indications for selected target animal species:
Treatment of infections caused by marbrofloxacin-susceptible strains of microorganisms.
• infections of the skin and soft tissues (dysfunction of skin folds, impetigo, folliculitis, furunculosis, cellulitis)
• urinary tract infections associated or not associated with prostatitis or epididymitis
• respiratory tract infections.
Contraindications:
Do not use marbofloxacin in dogs less than 12 months old, and in very large breeds with a longer growth period, such as German, Briard, Bernese Mountain Dog, Bouvier and Mastiff, do not use in dogs under 18 months of age.
Do not use in cases of hypersensitivity to fluoroquinolones or any of the product’s excipients.
Do not use quinolone resistance because there is (almost) complete cross-resistance to quinolones and other fluoroquinolones.
The drug is not suitable for treating infections caused by strictly anaerobic bacteria, yeast, or fungi.
Do not use the drug on cats. For this type of treatment, 20 mg tablets with a dividing line are available.
Special warnings for each target animal species:
Low pH urine can inhibit the action of marbofloxacin.
Special precautions for use:
Special precautions for use in animals:
Fluoroquinolones have been found to cause damage to articular cartilage in growing dogs and therefore attention should be paid to dosage, especially with the use of the drug in young animals.
The neurological side effects of fluoroquinolones are also known. Use with caution in dogs with known epilepsy.
Fluoroquinolones should be reserved for the treatment of diseases that have responded poorly, or that can be expected to respond poorly to treatment with other classes of antibacterial agents. Whenever possible, fluoroquinolone therapy should be based on the results of susceptibility tests. Using a product against the ChPLW recommendations may increase the incidence of fluoroquinolone resistant bacteria and reduce the effectiveness of treatment with other quinolones due to possible cross-resistance.
While using the drug, official and local antibiotic policy guidelines should be followed.
Special precautions to be taken by the person in charge of the veterinary medicinal product for animals:
People with known hypersensitivity to (fluorine) quinolones should avoid contact with the veterinary medicinal product.
If accidentally swallowed, seek medical advice immediately and show the package leaflet or label to the doctor in charge. Wash your hands after use.
Adverse reactions (frequency and severity):
For the recommended therapeutic doses, there should be no side effects in dogs. In particular, no joint damage was observed with the recommended doses. However, joint pain and / or neurological symptoms (ataxia, aggressive behavior, seizures, depression) rarely occur.
Allergic reactions (transient skin reactions) associated with the possible secretion of histamine have been observed.
Sometimes mild side effects such as vomiting, loose stools, increased thirst, and transient agitation can occur. These symptoms disappear spontaneously after treatment and do not require discontinuation of treatment.
The frequency of adverse reactions is presented in accordance with the following rule:
– very common (more than 1 in 10 animals showing activity (s) undesirable during one treatment cycle)
– often (more than 1, but less than 10 in 100 animals).
– unusual (more than 1, but less than 10 per 1000 animals).
– rarely (more than 1, but less than 10 per 10,000 animals).
– very rare (less than 1 in 10,000 animals, including individual reports).
Use during pregnancy, lactation or
Studies in pregnant rats and rabbits showed no adverse effects during pregnancy. However, no specific tests have been performed on pregnant dogs.
For use in pregnant animals and during lactation only after a benefit / risk assessment by a veterinarian.
Interaction with other medicinal products or other forms of interaction:
Interactions of fluoroquinolones with orally administered cations (aluminum, calcium, magnesium, iron) are known. In such cases, bioavailability may be reduced.
Do not use antibiotics in combination with tetracyclines and macrolides due to possible antagonistic effects.
With simultaneous use with theophylline, its half-life and plasma concentration increase. Therefore, the dose of theophylline should be reduced.
Dosage and route of administration:
Oral use.
Overdose (symptoms, emergency procedures, antidotes), if necessary:
Overdose can cause damage to the articular cartilage and acute symptoms in the form of neurological disorders (eg, salivation, watery eyes, chills, myoclonus, seizures), which should be treated symptomatically.
Withdrawal period (s):
Not applicable
PHARMACEUTICAL DATA:
List of fillers:
Lactose monohydrate
Cellulose powder
Povidone
Crospovidone
Colloidal anhydrous silicon dioxide
Calcium Behanate
Yeast
beef
Pharmaceutical incompatibility:
Not applicable
Shelf life:
Shelf life of packaged veterinary medicinal product: 3 years.
Shelf life of tablets, divided into halves: 4 days.
Special precautions for storage:
No special precautions regarding the storage temperature of the medicinal product.
Store blisters in their original packaging.
If tablets have been separated, the remaining halves should be stored in the vesicle cavity.
Any split tablets stored for more than 4 days should be removed.
The nature and composition of the immediate packaging:
Special precautions for disposal of unused veterinary medicinal product or waste derived from it:
